Mountain Valley MD Holdings Inc. (the “Company” or
“MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to
announce the appointment of Yong Yao to the role of Chief Financial
Officer effective January 15, 2024. The Company has accepted the
resignation of the Company’s current Chief Financial Officer, Lucie
Letellier, due to health issues that have resurfaced and require
Ms. Letellier to take a leave of absence from her professional
endeavours at this time. Ms. Letellier will continue to serve as
the Company’s Chief Financial Officer until January 15, 2024 and
assist with the transition to the new CFO.
“I am very pleased to welcome Yong Yao to the MVMD team to
support our commercialization growth phase and the scaling of our
operations globally,” said Dennis Hancock, President & CEO of
the Company. “Mr. Yao is a very accomplished CFO and has joined us
at a very important time as we navigate complex international
sales, royalty, and tax strategies.”
With a distinguished financial career spanning premier
institutions in both North America and the Far East, Mr. Yao is a
seasoned CFO and brings a wealth of expertise in financial markets,
corporate governance, and international business. In his recent
role as CFO of Hanalytics BioMind Co., Mr. Yao played a pivotal
role in securing USD 200 million dollars in private equity
financing and chartering the company’s profitable growth to a
valuation of USD 1.4 billion. Mr. Yao was the Executive Director of
Xinyuan Real Estate Corp. and President of Xin Yan Capital, a
Xinyuan subsidiary, where he managed private equity funds totaling
CNY 30 billion, facilitating successful IPOs, overseeing global
land acquisition and real estate projects. Mr. Yao’s leadership
roles at Bank of America Merrill Lynch, Morgan Stanley, and Scotia
Bank Canada showcased his diverse abilities, including strategic
financial oversight, implementation of accounting policies and IFRS
standards, regulatory reporting, management reporting, and
financial business planning. Notably, his entrepreneurial venture,
Selectin Biomedical Inc., secured substantial funding and
regulatory approvals for innovative small molecule chemical drugs
designed for anti-tumor applications. Mr. Yao holds an MBA from
McGill University, and two designations by AICPA-CIMA UK, including
Fellow Chartered Management Accountant (FCMA) and Chartered Global
Management Accountant (CGMA). Additionally, he holds a Bachelor of
Science degree in Biology from Nankai University.
The Company has granted stock options (the “Options”) to
Mr. Yao, in accordance with the terms and conditions of the
Company’s Stock Option Plan, to purchase 500,000 common shares in
the capital stock of the Company. The Options are exercisable for a
period of five years from the date of grant at a price of $0.05 per
share. The Options will vest 20% on the date of grant, 30% on the
6-month anniversary following the date of grant and the remaining
50% on the 12-month anniversary following the date of grant.
The Company extends its appreciation to outgoing CFO Lucie
Letellier for her contributions to the Company.
“Seeing the relapse in Lucie Letellier’s health is very
unfortunate and we respect the important need for her to focus on
her wellbeing with her family at this time,” continued Hancock. “We
are grateful for her support of MVMD and willingness to manage
through this transition window to minimize any potential disruption
to the business.”
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class organization
centered around the implementation, licensing and reselling of key
technologies and formulations:
- patented Quicksome™ oral formulation and delivery
technologies
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural
plant signalling technology
Consistent with its vision towards “More Life”, MVMD applies its
owned and licensed technologies to its work for advanced delivery
of molecules for human and husbandry animal applications, including
the development of products for pain management, weight loss,
energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work
with Agrarius is focused on generating a positive impact on crop
yields and reducing fertilizer usage.
MVMD’s patented Quicksome™ technology utilizes proprietary
formulations and stabilizing molecules to encapsulate and formulate
active ingredients into highly efficient product formats. The
result is a new generation of product formulations that could be
capable of delivering nutraceutical and drug molecules into the
body faster, with greater impact, efficiency and accuracy.
MVMD’s patented Quicksol™ technology covers all highly
solubilized macrocyclic lactones that could be effectively applied
in multiple viral applications that could positively impact human
and animal health globally.
MVMD’s licensed Agrairus™ agricultural plant signalling
technology that could be capable of application to agricultural
crops to naturally increase yields, reduce fertilizer usage, and
increase general resilience to pests and climate change.
For more Company information and contact details, visit
www.MVMD.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
Certain statements contained in this news release may constitute
forward-looking information. Forward-looking information is often,
but not always, identified by the use of words such as
"anticipate", "plan", "estimate", "expect", "may", "will",
"intend", "should", and similar expressions. Forward-looking
information involves known and unknown risks, uncertainties and
other factors that may cause actual results or events to differ
materially from those anticipated in such forward-looking
information.
The Company's actual results could differ materially from those
anticipated in this forward-looking information as a result of
regulatory decisions, competitive factors in the industries in
which the Company operates, prevailing economic conditions, and
other factors, many of which are beyond the control of the Company.
The Company is making forward-looking statements, including but not
limited to: The Company is making forward-looking statements
including but not limited to: the effective date of the appointment
of Mr. Yao; the continued delivery of services by Ms. Letellier and
the timing thereof; the terms of the options granted to Mr. Yao,
including the vesting terms thereof. The Company believes that the
expectations reflected in the forward-looking information are
reasonable, but no assurance can be given that these expectations
will prove to be correct and such forward-looking information
should not be unduly relied upon. Any forward-looking information
contained in this news release represents the Company's
expectations as of the date hereof and is subject to change after
such date. The Company disclaims any intention or obligation to
update or revise any forward-looking information whether as a
result of new information, future events or otherwise, except as
required by applicable securities legislation.
Neither the CSE nor OTC has reviewed or approved the contents of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231215915945/en/
For further information:
Dennis Hancock President and Chief Executive Officer Mountain
Valley MD Holdings Inc. Investor Relations @ 647-725-9755 Email:
info@mvmd.com www.MVMD.com
Mountain Valley MD (TG:20MP)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Mountain Valley MD (TG:20MP)
Historical Stock Chart
Von Dez 2023 bis Dez 2024